Polyrizon Ltd. (PLRZ)
Nasdaq · Healthcare · Biotechnology
$9.26−3.64%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $22.5M
- 52-week range
- $2.88 – $18.20
- 52-week change
- +45.61%
- EPS (trailing)
- −$4.97
Fiscal year to Dec 2025
- Net income
- −$3.3M
- Diluted EPS
- $4.90
- Free cash flow
- −$4.5M
From the company’s annual report on SEC EDGAR.
About Polyrizon Ltd.
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.
Headquarters: Ra'anana, Israel · 2 employees · polyrizon-biotech.com